Physician profile
Ashley Early
NPI 1588279475
$2,590.98
in general payments reported to CMS, 2019-2025
24 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $1,294 · 2024: $631 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,375.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $723.70 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $360.81 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $322.86 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $202.88 | 2022-2024 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $122.40 | 2022-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $113.42 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $112.27 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.14 | 2022-2023 | Jardiance |
| Inari Medical, INC. | $70.22 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $63.59 | 2022-2024 | Xarelto |
| Baxter Healthcare | $61.33 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $58.00 | 2023 | |
| Medtronic, INC. | $50.12 | 2023-2025 | Selectsecure, Linq II |
| Scpharmaceuticals INC. | $41.42 | 2023 | |
| Kiniksa Pharmaceuticals, LTD. | $34.64 | 2023 | Arcalyst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $20.21 | 2023 | Nexletol |
| Silk Road Medical, INC. | $18.79 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $18.71 | 2025 | Ranger |
| Phathom Pharmaceuticals, INC. | $18.01 | 2024 | Voquezna |
| Kiniksa Pharmaceuticals International, Plc | $17.68 | 2024 | Arcalyst |
| Elutia, INC. | $17.28 | 2023 | |
| Celgene Corporation | $16.32 | 2023 | Zeposia |
| Inspire Medical Systems, INC. | $14.97 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $14.21 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Early listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.